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Evidence for treating malaria with artemisinin-based 
combination therapy in the first trimester of pregnancy
Treatment of malaria during pregnancy requires 
balancing the need for radical cure while avoiding 
teratogenic exposure. In The Lancet Infectious Diseases, 
Makoto Saito and colleagues report the results of 
a systematic review and meta-analysis that used 
individual patient data on antimalarial efficacy and 
tolerability in pregnancy.1 This impressive undertaking 
comprises nearly all published evidence and clearly 
highlights the superiority of artemisinin-based combi-
nation therapy (ACT) over quinine monotherapy, 
building on previous studies that focused on ACT safety 
in the second and third trimesters.2
Quinine has been the only treatment for malaria in 
much of the world over the past four centuries, with 
the first reported use for a microscopically confirmed 
diagnosis of malaria during pregnancy in 1908.3 WHO 
recommends quinine for the treatment of malaria in the 
first trimester, ideally in combination with clindamycin. 
First-trimester use of ACTs is only advised when quinine 
is not available.4 However, because clindamycin is 
rarely available at the point of care in malaria-endemic 
countries, the vast majority of pregnant women 
diagnosed with first-trimester malaria are given quinine 
monotherapy, or an ACT if pregnancy is not recognised.5,6
Saito and colleagues found that quinine plus 
clindamycin had a similar PCR-corrected efficacy 
on day 28 compared to artemether-lumefantrine 
(AL; 99·9% vs 96·9%, respectively; adjusted hazard 
ratio 0·48 [95% CI 0·04–5·24]), whereas quinine 
monotherapy had an efficacy of only 87·7% (6·11, 
2·57–14·57) compared to AL. The substantially lower 
efficacy of quinine monotherapy versus AL is further 
evidence to support the change to WHO’s treatment 
guidelines recommended by the Malaria Policy Action 
Committee in 2016.7
Although only 33 of 4968 total episodes in the meta-
analysis were in their first trimester, there is no evidence 
to suggest that the relative efficacy of antimalarials in 
the first trimester would differ from treatment later in 
pregnancy. Moreover, the higher efficacy of artemisinin 
over quinine is more apparent in severe disease for 
which parenteral artemisinin is already the preferred 
option.4
It is difficult to draw conclusions regarding safety 
given the very small number of first-trimester preg-
nancies in this study. However, the safety of ACT in 
pregnancy is supported by data for 30 618 pregnancies 
(947 exposed to quinine and 717 exposed to ACTs 
in the first trimester) that showed that the risk of 
miscarriage and stillbirth are similar between ACTs and 
quinine. Compared with quinine, the risk of ACTs on 
miscarriage were 0·73 (95% CI 0·44–1·21) and the risk 
of ACT on stillbirth were 0·29 (0·08–1·02).8 Neither 
ACTs nor quinine were associated with an increased risk 
of stillbirth compared with no antimalarial treatment 
in the first trimester. Quinine administered in the 
first trimester was associated with increased risk of 
miscarriage compared with no antimalarial treatment, 
although ACTs were not. The risks of congenital 
malformations from quinine and ACTs were similar. 
These numbers are only sufficient to exclude a greater 
than approximately two-fold increase in the risk of 
miscarriage and stillbirth, underscoring the need for 
more data.8 However, it has taken two decades to 
collect the evidence to date, and it is unlikely that more 
data will be available soon. There is also the issue of 
poor tolerability associated with quinine, whereby a 
very high proportion of patients reported symptoms 
of cinchonism, including tinnitus, by day 7 of therapy.9 
These adverse effects might be so bothersome that 
therapy is discontinued prematurely, further reducing 
its efficacy. Effective treatment clearly reduces the risk 
of stillbirth caused by malaria infection.10 Therefore, 
even if it was ensured that all first-trimester women 
with parasitaemia receive quinine plus clindamycin for 
7 days, these patients might not be optimally served.
Today, there are insufficient safety data for the use 
of ACTs in first trimester to argue for their use in first 
trimester for scenarios in which malaria testing is not 
done before dosing (eg, mass drug administration) 
or for scenarios in which the drug is provided 
prophylactically (eg, intermittent preventive treatment 
in pregnancy). However, considering the evidence base 
of efficacy, adherence, and tolerability, the risk-benefit 
analysis for treatment favours the use of ACTs for 
confirmed malaria in the first trimester of pregnancy.7
Comment
2 www.thelancet.com/infection   Published online April 29, 2020   https://doi.org/10.1016/S1473-3099(20)30131-6
We declare no competing interests.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open 
Access article under the CC BY-NC-ND 4.0 license.
*Julie R Gutman, R Matthew Chico
fff2@cdc.gov
Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Global 
Health, US Centers for Diseases Control and Prevention, Atlanta, GA 30329, USA 
(JRG); Department of Disease Control, Faculty of Infectious and Tropical Disease, 
London School of Hygiene & Tropical Medicine, London, UK (RMC)
1 Saito M, Mansoor R, Kennnon K, et al. Efficacy and tolerability of artemisinin-
based and quinine-based treatments for uncomplicated falciparum malaria 
in pregnancy: a systematic review and individual patient data meta-analysis. 
Lancet Infect Dis 2020; published online April 29. https://doi.org/10.1016/
S1473-3099(20)30064-5.
2 Kovacs SD, van Eijk AM, Sevene E, et al. The safety of artemisinin 
derivatives for the treatment of malaria in the 2nd or 3rd trimester of 
pregnancy: a systematic review and meta-analysis. PLoS One 2016; 
11: e0164963.
3 Maxwell JP. The use of quinine during pregnancy, labour and the 
puerperium. J Trop Med Hyg 1908; 11: 191–94.
4 WHO. Guidelines for the treatment of malaria, 3rd edn. Geneva: World 
Health Organization, 2015.
5 Hill J, D’Mello-Guyett L, Hoyt J, van Eijk AM, ter Kuile FO, Webster J. 
Women’s access and provider practices for the case management of 
malaria during pregnancy: a systematic review and meta-analysis. 
PLoS Med 2014; 11: e1001688.
6 Riley C, Dellicour S, Ouma P, et al. Knowledge and adherence to the national 
guidelines for malaria case management in pregnancy among healthcare 
providers and drug outlet dispensers in rural, western Kenya. PLoS One 
2016; 11: e0145616.
7 WHO malaria policy advisory committee and secretariat. Malaria policy 
advisory committee to the WHO: conclusions and recommendations of 
eighth biannual meeting (September 2015). Malar J 2016; 15: 117.
8 Dellicour S, Sevene E, McGready R, et al. First-trimester artemisinin 
derivatives and quinine treatments and the risk of adverse pregnancy 
outcomes in Africa and Asia: a meta-analysis of observational studies. 
PLoS Med 2017; 14: e1002290.
9 White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. 
Quinine pharmacokinetics and toxicity in cerebral and uncomplicated 
Falciparum malaria. Am J Med 1982; 73: 564–72.
10 Moore KA, Simpson JA, Scoullar MJL, McGready R, Fowkes FJI. Quantification 
of the association between malaria in pregnancy and stillbirth: a systematic 
review and meta-analysis. Lancet Glob Health 2017; 5: e1101–12.
